NCT00268671已完成1 期
Phase I/II Trial of Weekly Docetaxel and Cisplatin for Locoregional Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Sanofi
- 入组人数
- 45
- 主要终点
- AE SAE collection
研究概览
简要总结
Study Objectives:
- To determine the MTD (maximal tolerated dose) and recommended dose of a weekly docetaxel and cisplatin combination regimen for locoregional recurrent/metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- To determine the response rate of the recommended dose
- To determine the safety and tolerability of the recommended dose
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed (of original primary tumor) locoregional recurrent and/or metastatic following prior radiotherapy and/or surgery and not amenable to further curative local therapy for SCCHN
- •Measurable disease as defined by at least the longest diameter measured as 20 mm by conventional CT or 10 mm by spiral CT. Physical measurements are allowed if longest diameter is 20 mm by caliper measurements.
- •ECOG performance status 0-2
- •Adequate bone marrow and hepatic function as evidenced by the following:
- •Hematology (Bone marrow):
- •Neutrophils ≥ 1.50 x 10^9/L
- •Platelets ≥ 100 x 10^9/L
- •Hemoglobin ≥ 10 g/dL
- •Hepatic function:
- •AST and/or ALT: < 2X ULN (Upper Limit of Normal)
- •Bilirubin < 1X ULN
- •Adequate renal function with calculated or measured glomerular filtration rate of > 60 ml/min calculated by the Cockcroft- Gault method
- •No severe intercurrent illness or other serious illness or medical conditions including but not limited to:
- •Unstable cardiac disease despite treatment, myocardial infarction within 6 months prior to study entry.
- •Active uncontrolled infection
- •Active peptic ulcer
- •Chronic obstructive pulmonary disease requiring hospitalization during the year preceding study entry
- •No prior chemotherapy for recurrent/advanced SCCHN with platinum or taxane regimen (primary radiosensitizing platinum allowed).
- •No other diagnosed malignancy other than basal cell carcinoma of the skin or cervix carcinoma in situ
排除标准
- •Prior therapy with taxanes either adjuvant, neoadjuvant, concurrent or in advanced stage disease
- •Prior chemotherapy for locoregional recurrent/metastatic SCCHN with palliative intent
- •Contraindications from
- •the medical history (i.e. known hepatitis, HIV) and physical exam
- •laboratory tests (hematology, biochemistry)
- •12-lead electrocardiogram
- •blood pressure and pulse
- •Pregnancy
- •Breast-feeding
- •Treatment with any investigational product in the last 4 weeks before study entry
- •Likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol
- •Presence or sequelae of gastrointestinal, liver or kidney disease, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs
- •History of hypersensitivity to the study drug(s) or to drugs with a similar chemical structure
- •Impaired hepatic function, as shown by bilirubin greater than upper limits of normal and/or AST greater than 2 times upper limits of normal
- •Impaired renal function, as shown by measured or calculated creatinine clearance of < 60 ml/min or absolute creatinine level > 1.5 upper limit of normal
结局指标
主要结局
AE SAE collection
时间窗: from the inform consent signed up to the end of the study
次要结局
未报告次要终点
研究者
相似试验
Unknown
2 期
Weekly Docetaxel Plus Cisplatin as the First-line Therapy for Nasopharyngeal CancerNasopharyngeal CancerNCT01312311Samsung Medical Center51
已完成
1 期
Phase I/II Study of TPF as First-line Chemotherapy in Patients With Metastatic Esophageal Cancer.Esophageal CancerNCT00209690Hokkaido Gastrointestinal Cancer Study Group30
已完成
1 期
Phase I/II Study of Taxotere,CDDP and 5-FU(TPF) in Pre-treated Pts With Metastatic Esophageal Cancer.Esophageal CancerNCT00209716Hokkaido Gastrointestinal Cancer Study Group30
Unknown
2 期
Weekly Docetaxel Plus Cisplatin or Oxaliplatin for AGCStomach NeoplasmStage IVRecurrentNCT00510107Gachon University Gil Medical Center90
已完成
1 期
Chemotherapy for Patients With Cancer of the StomachFirst-line Treatment for Patients With Non-resectable Gastric Cancer or Cancer of the Esophagus orNCT01928524Per Pfeiffer34